Table 2.
Clinical characteristics of asthmatic children before, 3 and 6 months after inhaled corticosteroid therapy
| Parameters | Before | 3 months | 6 months | Test p |
|---|---|---|---|---|
| PEF (%) (mean±SD) |
|
|
|
ANOVA |
| mPA |
81.2±17.3 |
90.6±23.6 |
99.2±18.4 |
p < 0.05* |
| MPA |
75.6±15.3 |
79.3±16.8 |
86.3±18.3 |
p < 0.05* |
| SPA |
65.6±12.0 |
72.8±17.0 |
77.9±19.8 |
p > 0.05 |
| BMI (Kg/m2) (mean±SD) |
|
|
|
|
| mPA |
51.9±34.3 |
45.2±32.2 |
43.4±37.5 |
Kruskal-Wallis p>0.05 |
| MPA |
47.4±31.2 |
50.5±31.5 |
50.0±30.5 |
|
| SPA |
63.7±32.5 |
61.8±29.6 |
63.2±29.5 |
|
| ACT n (%) |
|
|
|
|
| mPA |
|
|
|
|
| ≥25 |
0/23 (0%) |
1/23 (4.3%) |
4/22 (18.2%) |
Chi-square |
| 20-24** |
11/23 (47.8%) |
19/23 (82.6%) |
16/22 (72.7%) |
p<0.05 |
| <20*** |
12/23 (52.2%) |
3/23 (13.0%) |
2/22 (9.1%) |
|
| MPA |
|
|
|
|
| ≥25 |
0/20 0%) |
1/20 (5%) |
3/20 (15%) |
Chi-square |
| 20-24** |
2/20 (10%) |
7/20 (35%) |
10/20 (50.0%) |
p<0.05 |
| <20*** |
18/20 (90%) |
12/20 (60%) |
7/20 (35.0%) |
|
| SPA |
|
|
|
|
| ≥25 |
0/14 (0%) |
0/14 (0%) |
0/14 (0%) |
Chi-square |
| 20-24 |
2/14 (14.3%) |
3/14 (21.4%) |
4/14 (28.6%) |
p>0.05 |
| <20 | 12/14 (85.7%) | 11/14 (78.57%) | 10/14 (71.4%) |
PEF Peak Expiratory Flow, BMI Body Mass Index (percentile), ACT Asthma Control Test, mPA mild persistent asthma, MPA moderate persistent asthma, SPA severe persistent asthma, * 6 m > before ** 3 m and 6 m > before *** 3 m and 6 m < before.